Company news

MAIA Biotechnology, Inc. news in 2025

MAIA Biotechnology, Inc.'s news releases, calls and decks from 2025, newest first.

View company

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

December 24, 2025

MAIA Biotechnology Announces $1.51 Million Private Placement

December 16, 2025

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

December 11, 2025

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

December 1, 2025

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

November 21, 2025

MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation

November 20, 2025

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 27, 2025

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

October 23, 2025

MAIA Biotechnology Announces $736,600 Private Placement

October 13, 2025

MAIA Biotechnology Announces $2.25 Million Private Placement

September 29, 2025

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

September 24, 2025

MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

September 11, 2025

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

September 5, 2025

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

August 27, 2025

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

August 13, 2025

MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

July 28, 2025

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

July 17, 2025

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

July 9, 2025

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

July 1, 2025

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

June 24, 2025

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

June 18, 2025

MAIA Biotechnology to Present at BIO International Convention 2025

June 10, 2025

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

June 5, 2025

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

June 5, 2025

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 15, 2025

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 14, 2025

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025

MAIA Biotechnology Announces $1.08 Million Private Placement

May 5, 2025

Decks in 2025